Clinical trial
Targeting of Renal Cell Cancer With Specific Inhibitors: A Model for Selective Adaptive Medicine Based on Molecular Alterations
NCT02560012 is registered in ClinicalTrials.gov with The University of Texas Health Science Center, Houston as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Targeting of Renal Cell Cancer With Specific Inhibitors: A Model for Selective Adaptive Medicine Based on Molecular Alterations
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 4, 2016
- Completion date
- July 27, 2017
- Enrollment
- 4 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.